SUPPLEMENT

Q3 2026 — Other Financial Disclosures

Q3 2026PDF · 17 pages615 KB
Table 1: Sales by Segment 1
Table 2: Sales by Geographic Area 2
Table 3: Sales of Key Products/Franchises 3 - 7
Table 4: Condensed Consolidated Statement of Earnings - QTD 8
Table 5: Condensed Consolidated Statement of Earnings - YTD 9
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 10
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 11
Table 8: Non-GAAP Adjusted Net Earnings 12
Table 9: Non-GAAP P&L by Segment Reconciliation 2026 - QTD 13
Table 10: Non-GAAP P&L by Segment Reconciliation 2025 - QTD 14
Table 11: Non-GAAP P&L by Segment Reconciliation 2026 - YTD 15
Table 12: Non-GAAP P&L by Segment Reconciliation 2025 - YTD 16
Third Quarter 2026
Other Financial Disclosures
Table of Contents

-- 1 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2026 2025 Total Operations Currency 2026 2025 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 10,447	$ 9,402 11.1 % 11.1 - 29,297	$ 26,655 9.9 % 9.9 -
International 6,310 6,161 2.4 3.0 (0.6) 19,270 17,983 7.2 3.6 3.6
16,757 15,563 7.7 7.9 (0.2) 48,567 44,638 8.8 7.4 1.4
MedTech
U.S. 4,512 4,306 4.8 4.8 - 13,525 12,902 4.8 4.8 -
International 4,130 4,124 0.1 0.1 0.0 12,679 12,089 4.9 2.2 2.7
8,642 8,430 2.5 2.5 0.0 26,204 24,991 4.9 3.5 1.4
U.S. 14,959 13,708 9.1 9.1 - 42,822 39,557 8.3 8.3 -
International 10,440 10,285 1.5 1.8 (0.3) 31,949 30,072 6.2 3.0 3.2
Worldwide 25,399	$ 23,993 5.9 % 6.0 (0.1) 74,771	$ 69,629 7.4 % 6.0 1.4
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
THIRD QUARTER NINE MONTHS
Percent Change

-- 2 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2026 2025 Total Operational Currency 2026 2025 Total Operational Currency
Sales to customers by
geographic area
U.S. 14,959	$ 13,708 9.1 % 9.1 - 42,822	$ 39,557 8.3 % 8.3 -
Europe 5,405 5,440 (0.6) 1.0 (1.6) 16,979 15,937 6.5 2.3 4.2
Western Hemisphere excluding U.S. 1,385 1,231 12.5 8.0 4.5 3,987 3,604 10.6 4.5 6.1
Asia-Pacific, Africa 3,650 3,614 1.0 1.0 0.0 10,983 10,531 4.3 3.6 0.7
International 10,440 10,285 1.5 1.8 (0.3) 31,949 30,072 6.2 3.0 3.2
Worldwide 25,399	$ 23,993 5.9 % 6.0 (0.1) 74,771	$ 69,629 7.4 % 6.0 1.4
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
THIRD QUARTER NINE MONTHS
Percent Change

-- 3 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
ONCOLOGY
US 4,267	$ 3,468 23.0% 23.0% - 11,951	$ 9,866 21.1% 21.1% -
Intl 3,335 3,060 9.0% 9.5% (0.5)% 10,030 8,652 15.9% 11.9% 4.0%
WW 7,602 6,529 16.4% 16.7% (0.3)% 21,981 18,519 18.7% 16.8% 1.9%
DARZALEX
US 2,528 2,088 21.1% 21.1% - 7,171 5,934 20.9% 20.9% -
Intl 1,711 1,584 8.0% 8.5% (0.5)% 5,239 4,514 16.1% 11.9% 4.2%
WW 4,239 3,672 15.4% 15.6% (0.2)% 12,410 10,448 18.8% 17.0% 1.8%
CARVYKTI
US 472 396 19.4% 19.4% - 1,377 1,072 28.5% 28.5% -
Intl 238 128 85.3% 84.1% 1.2% 587 260 * * *
WW 710 524 35.5% 35.2% 0.3% 1,964 1,332 47.4% 45.5% 1.9%
TECVAYLI
US 236 115 * * - 549 334 64.4% 64.4% -
Intl 77 62 24.0% 25.9% (1.9)% 225 160 40.6% 37.7% 2.9%
WW 312 177 76.6% 77.3% (0.7)% 774 494 56.7% 55.7% 1.0%
TALVEY
US 112 85 31.6% 31.6% - 325 235 38.1% 38.1% -
Intl 59 37 62.9% 66.9% (4.0)% 172 79 * * *
WW 171 122 40.9% 42.1% (1.2)% 497 314 58.3% 57.5% 0.8%
RYBREVANT / LAZCLUZE
US 201 136 47.9% 47.9% - 566 388 46.1% 46.1% -
Intl 119 61 94.5% 98.3% (3.8)% 300 130 * * *
WW 320 198 62.3% 63.5% (1.2)% 866 518 67.4% 67.5% (0.1)%
ERLEADA
US 423 378 11.8% 11.8% - 1,161 1,048 10.8% 10.8% -
Intl 600 558 7.7% 7.7% 0.0% 1,806 1,567 15.3% 10.8% 4.5%
WW 1,023 936 9.4% 9.4% 0.0% 2,967 2,615 13.5% 10.8% 2.7%
IMBRUVICA
US 145 211 (31.6)% (31.6)% - 437 685 (36.3)% (36.3)% -
Intl 420 483 (13.2)% (12.6)% (0.6)% 1,386 1,453 (4.7)% (8.7)% 4.0%
WW 563 695 (18.8)% (18.4)% (0.4)% 1,822 2,139 (14.8)% (17.5)% 2.7%
OTHER ONCOLOGY (3)
US 149 61 * * - 365 171 * * -
Intl 111 147 (24.4)% (23.9)% (0.5)% 314 488 (35.7)% (36.0)% 0.3%
WW 262 207 26.3% 26.7% (0.4)% 680 659 3.2% 2.9% 0.3%
See footnotes at end of schedule
% Change	% Change

-- 4 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
IMMUNOLOGY
US 2,804	$ 2,676 4.8% 4.8% - 7,031	$ 7,377 (4.7)% (4.7)% -
Intl 1,417 1,493 (5.1)% (4.8)% (0.3)% 4,414 4,492 (1.7)% (4.9)% 3.2%
WW 4,221 4,168 1.3% 1.4% (0.1)% 11,445 11,868 (3.6)% (4.8)% 1.2%
TREMFYA
US 1,772 989 79.1% 79.1% - 4,279 2,384 79.5% 79.5% -
Intl 624 434 43.7% 43.4% 0.3% 1,771 1,181 49.9% 44.7% 5.2%
WW 2,396 1,424 68.3% 68.2% 0.1% 6,050 3,566 69.7% 67.9% 1.8%
SIMPONI / SIMPONI ARIA
US 269 309 (13.2)% (13.2)% - 798 906 (11.9)% (11.9)% -
Intl 299 377 (20.6)% (20.3)% (0.3)% 1,035 1,130 (8.4)% (11.4)% 3.0%
WW 568 687 (17.3)% (17.1)% (0.2)% 1,833 2,036 (10.0)% (11.6)% 1.6%
REMICADE
US 258 326 (20.8)% (20.8)% - 742 923 (19.6)% (19.6)% -
US Exports (4) 12 19 (37.1)% (37.1)% - 40 63 (36.6)% (36.6)% -
Intl 124 132 (6.2)% (7.5)% 1.3% 372 413 (9.8)% (12.9)% 3.1%
WW 394 476 (17.3)% (17.6)% 0.3% 1,154 1,398 (17.5)% (18.4)% 0.9%
STELARA
US 368 1,022 (64.0)% (64.0)% - 924 3,081 (70.0)% (70.0)% -
Intl 349 549 (36.5)% (35.5)% (1.0)% 1,188 1,768 (32.8)% (34.9)% 2.1%
WW 716 1,570 (54.4)% (54.0)% (0.4)% 2,112 4,848 (56.4)% (57.2)% 0.8%
OTHER IMMUNOLOGY
US 126 12 * * - 249 21 * * -
Intl 21 0 * * * 48 0 * * *
WW 147 12 * * * 297 21 * * *
NEUROSCIENCE
US 1,733 1,367 26.8% 26.8% - 4,886 3,712 31.6% 31.6% -
Intl 642 658 (2.4)% (1.7)% (0.7)% 2,001 2,011 (0.5)% (3.0)% 2.5%
WW 2,375 2,024 17.3% 17.6% (0.3)% 6,887 5,722 20.3% 19.5% 0.8%
SPRAVATO
US 559 405 37.9% 37.9% - 1,479 1,047 41.3% 41.3% -
Intl 66 53 22.7% 21.4% 1.3% 197 146 34.8% 28.1% 6.7%
WW 624 459 36.1% 36.0% 0.1% 1,676 1,193 40.5% 39.7% 0.8%
CAPLYTA (5)
US 398 240 66.1% 66.1% - 1,029 451 * * -
Intl - - - - - - - - - -
WW 398 240 66.1% 66.1% - 1,029 451 * * -
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 739 664 11.4% 11.4% - 2,235 2,021 10.6% 10.6% -
Intl 258 267 (3.0)% (2.4)% (0.6)% 816 804 1.5% (0.8)% 2.3%
WW 998 929 7.3% 7.5% (0.2)% 3,051 2,824 8.0% 7.4% 0.6%
CONCERTA / Methylphenidate
US 6 14 (56.3)% (56.3)% - 40 76 (47.3)% (47.3)% -
Intl 138 127 8.1% 8.9% (0.8)% 386 376 2.4% 1.1% 1.3%
WW 143 140 2.1% 2.9% (0.8)% 425 452 (5.9)% (7.0)% 1.1%
OTHER NEUROSCIENCE
US 32 46 (30.6)% (30.6)% - 104 119 (12.6)% (12.6)% -
Intl 180 210 (14.3)% (13.1)% (1.2)% 602 684 (12.0)% (14.5)% 2.5%
WW 212 256 (17.3)% (16.2)% (1.1)% 706 803 (12.1)% (14.2)% 2.1%
See footnotes at end of schedule
% Change	% Change

-- 5 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
PULMONARY HYPERTENSION (PH)
US 588	$ 815 (27.8)% (27.8)% - 2,233	$ 2,358 (5.3)% (5.3)% -
Intl 309 300 2.9% 4.1% (1.2)% 942 895 5.2% 2.9% 2.3%
WW 897 1,115 (19.5)% (19.2)% (0.3)% 3,175 3,253 (2.4)% (3.0)% 0.6%
UPTRAVI
US 383 392 (2.2)% (2.2)% - 1,154 1,139 1.3% 1.3% -
Intl 100 92 8.9% 8.4% 0.5% 306 272 12.7% 7.9% 4.8%
WW 483 484 (0.1)% (0.2)% 0.1% 1,460 1,411 3.5% 2.6% 0.9%
OPSUMIT / OPSYNVI
US 193 409 (52.8)% (52.8)% - 1,042 1,175 (11.3)% (11.3)% -
Intl 179 168 5.9% 7.8% (1.9)% 538 507 6.0% 4.4% 1.6%
WW 372 578 (35.7)% (35.2)% (0.5)% 1,580 1,682 (6.1)% (6.6)% 0.5%
OTHER PULMONARY HYPERTENSION
US 12 13 (7.3)% (7.3)% - 37 44 (15.5)% (15.5)% -
Intl 30 39 (23.8)% (21.2)% (2.6)% 98 116 (15.6)% (15.3)% (0.3)%
WW 42 53 (19.7)% (17.7)% (2.0)% 135 160 (15.6)% (15.4)% (0.2)%
INFECTIOUS DISEASES (ID)
US 317 326 (2.7)% (2.7)% - 959 961 (0.2)% (0.2)% -
Intl 496 501 (1.2)% (0.1)% (1.1)% 1,506 1,472 2.3% (1.7)% 4.0%
WW 813 829 (1.8)% (1.1)% (0.7)% 2,465 2,434 1.3% (1.1)% 2.4%
EDURANT / rilpivirine
US 5 7 (31.6)% (31.6)% - 15 21 (30.1)% (30.1)% -
Intl 382 378 1.0% 2.4% (1.4)% 1,131 1,082 4.5% 0.6% 3.9%
WW 386 385 0.4% 1.8% (1.4)% 1,145 1,103 3.8% 0.0% 3.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 307 315 (2.5)% (2.5)% - 937 932 0.6% 0.6% -
Intl 74 81 (8.9)% (7.7)% (1.2)% 259 264 (1.9)% (6.2)% 4.3%
WW 381 397 (3.8)% (3.6)% (0.2)% 1,196 1,196 0.0% (0.9)% 0.9%
OTHER INFECTIOUS DISEASES
US 5 4 29.9% 29.9% - 7 8 (11.4)% (11.4)% -
Intl 40 42 (6.2)% (7.9)% 1.7% 116 126 (8.0)% (11.7)% 3.7%
WW 46 47 (3.0)% (4.5)% 1.5% 124 135 (8.2)% (11.7)% 3.5%
CARDIOVASCULAR / METABOLISM / OTHER (CVM)
US 736 750 (1.9)% (1.9)% - 2,235 2,381 (6.1)% (6.1)% -
Intl 112 149 (24.3)% (23.8)% (0.5)% 378 461 (17.9)% (20.9)% 3.0%
WW 849 899 (5.6)% (5.5)% (0.1)% 2,614 2,842 (8.0)% (8.5)% 0.5%
XARELTO
US 653 635 2.7% 2.7% - 1,959 1,946 0.7% 0.7% -
Intl - - - - - - - - - -
WW 653 635 2.7% 2.7% - 1,959 1,946 0.7% 0.7% -
OTHER
US 84 115 (27.2)% (27.2)% - 276 435 (36.5)% (36.5)% -
Intl 112 149 (24.3)% (23.8)% (0.5)% 378 461 (17.9)% (20.9)% 3.0%
WW 197 264 (25.5)% (25.3)% (0.2)% 655 896 (26.9)% (28.5)% 1.6%
TOTAL PH, ID, CVM
US 1,643 1,891 (13.2)% (13.2)% - 5,428 5,700 (4.8)% (4.8)% -
Intl 917 950 (3.5)% (2.5)% (1.0)% 2,826 2,828 (0.1)% (3.4)% 3.3%
WW 2,560 2,843 (9.9)% (9.6)% (0.3)% 8,254 8,529 (3.2)% (4.3)% 1.1%
TOTAL INNOVATIVE MEDICINE
US 10,447 9,402 11.1% 11.1% - 29,297 26,655 9.9% 9.9% -
Intl 6,310 6,161 2.4% 3.0% (0.6)% 19,270 17,983 7.2% 3.6% 3.6%
WW 16,757	$ 15,563 7.7% 7.9% (0.2)% 48,567	$ 44,638 8.8% 7.4% 1.4%
See footnotes at end of schedule
% Change	% Change

-- 6 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
MEDTECH SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,397	$ 1,306 7.0% 7.0% - 4,222	$ 3,931 7.4% 7.4% -
Intl 910 908 0.2% (0.2)% 0.4% 2,866 2,698 6.2% 3.4% 2.8%
WW 2,307 2,213 4.3% 4.1% 0.2% 7,088 6,629 6.9% 5.8% 1.1%
ELECTROPHYSIOLOGY
US 771 720 7.0% 7.0% - 2,290 2,145 6.8% 6.8% -
Intl 717 698 2.8% 1.8% 1.0% 2,219 2,064 7.5% 4.3% 3.2%
WW 1,487 1,418 4.9% 4.4% 0.5% 4,509 4,209 7.1% 5.6% 1.5%
ABIOMED
US 335 336 (0.3)% (0.3)% - 1,066 1,035 3.0% 3.0% -
Intl 78 86 (10.4)% (6.5)% (3.9)% 275 256 7.2% 5.4% 1.8%
WW 412 423 (2.3)% (1.5)% (0.8)% 1,340 1,291 3.8% 3.5% 0.3%
SHOCKWAVE
US 261 220 18.8% 18.8% - 771 659 17.0% 17.0% -
Intl 64 59 9.3% 11.2% (1.9)% 194 169 14.8% 15.1% (0.3)%
WW 325 278 16.8% 17.2% (0.4)% 965 828 16.6% 16.6% 0.0%
OTHER CARDIOVASCULAR
US 31 30 3.6% 3.6% - 96 93 3.2% 3.2% -
Intl 50 65 (21.9)% (23.1)% 1.2% 177 209 (15.0)% (17.7)% 2.7%
WW 81 95 (13.9)% (14.7)% 0.8% 273 302 (9.4)% (11.3)% 1.9%
SURGERY
US 1,070 1,031 3.7% 3.7% - 3,210 3,076 4.3% 4.3% -
Intl 1,459 1,511 (3.4)% (4.2)% 0.8% 4,483 4,417 1.5% (1.6)% 3.1%
WW 2,528 2,542 (0.6)% (1.0)% 0.4% 7,692 7,493 2.7% 0.8% 1.9%
ADVANCED
US 500 477 5.1% 5.1% - 1,476 1,411 4.7% 4.7% -
Intl 654 688 (5.0)% (5.7)% 0.7% 1,991 1,991 0.0% (2.9)% 2.9%
WW 1,155 1,165 (0.9)% (1.3)% 0.4% 3,467 3,402 1.9% 0.2% 1.7%
GENERAL
US 568 555 2.4% 2.4% - 1,733 1,666 4.0% 4.0% -
Intl 805 823 (2.2)% (3.0)% 0.8% 2,492 2,426 2.7% (0.6)% 3.3%
WW 1,373 1,378 (0.3)% (0.8)% 0.5% 4,225 4,092 3.3% 1.3% 2.0%
See footnotes at end of schedule
% Change	% Change

-- 7 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
VISION
US 596	$ 571 4.3% 4.3% - 1,740	$ 1,694 2.7% 2.7% -
Intl 865 828 4.4% 5.6% (1.2)% 2,537 2,354 7.8% 6.3% 1.5%
WW 1,461 1,400 4.4% 5.1% (0.7)% 4,277 4,048 5.6% 4.8% 0.8%
CONTACT LENSES / OTHER
US 465 456 1.9% 1.9% - 1,378 1,337 3.1% 3.1% -
Intl 588 562 4.7% 6.2% (1.5)% 1,669 1,565 6.6% 5.5% 1.1%
WW 1,053 1,018 3.5% 4.3% (0.8)% 3,047 2,902 5.0% 4.4% 0.6%
SURGICAL
US 132 116 13.6% 13.6% - 363 358 1.4% 1.4% -
Intl 276 266 3.8% 4.3% (0.5)% 867 789 10.0% 8.0% 2.0%
WW 408 383 6.8% 7.1% (0.3)% 1,230 1,147 7.3% 5.9% 1.4%
ORTHOPAEDICS
US 1,448 1,396 3.8% 3.8% - 4,353 4,200 3.6% 3.6% -
Intl 898 878 2.2% 2.9% (0.7)% 2,794 2,620 6.6% 3.5% 3.1%
WW 2,345 2,274 3.2% 3.4% (0.2)% 7,146 6,820 4.8% 3.6% 1.2%
HIPS
US 271 262 3.5% 3.5% - 831 796 4.4% 4.4% -
Intl 148 144 2.6% 3.0% (0.4)% 465 440 5.7% 2.1% 3.6%
WW 419 405 3.1% 3.3% (0.2)% 1,296 1,235 4.9% 3.6% 1.3%
KNEES
US 221 216 2.1% 2.1% - 688 673 2.2% 2.2% -
Intl 165 160 3.0% 4.4% (1.4)% 528 482 9.7% 7.1% 2.6%
WW 386 377 2.5% 3.1% (0.6)% 1,216 1,155 5.3% 4.2% 1.1%
TRAUMA
US 555 512 8.6% 8.6% - 1,623 1,515 7.1% 7.1% -
Intl 288 281 2.4% 2.8% (0.4)% 880 818 7.6% 4.4% 3.2%
WW 844 793 6.4% 6.5% (0.1)% 2,504 2,333 7.3% 6.2% 1.1%
SPINE, SPORTS & OTHER
US 401 406 (1.2)% (1.2)% - 1,211 1,216 (0.4)% (0.4)% -
Intl 296 293 1.3% 2.0% (0.7)% 920 881 4.5% 1.5% 3.0%
WW 697 698 (0.1)% 0.1% (0.2)% 2,131 2,096 1.7% 0.4% 1.3%
TOTAL MEDTECH
US 4,512 4,306 4.8% 4.8% - 13,525 12,902 4.8% 4.8% -
Intl 4,130 4,124 0.1% 0.1% 0.0% 12,679 12,089 4.9% 2.2% 2.7%
WW 8,642	$ 8,430 2.5% 2.5% 0.0% 26,204	$ 24,991 4.9% 3.5% 1.4%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of ZYTIGA which were previously disclosed separately
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change	% Change

-- 8 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 25,399	$ 100.0 23,993	$ 100.0 5.9
Cost of products sold 8,097 31.9 7,303 30.4 10.9
Gross Profit 17,302 68.1 16,690 69.6 3.7
Selling, marketing and administrative expenses 6,285 24.7 5,922 24.7 6.1
Research and development expense 4,652 18.3 3,672 15.3 26.7
In-process research and development impairments 339 1.4 - -
Interest (income) expense, net 31 0.1 18 0.1
Other (income) expense, net 5,780 22.8 (478) (2.0)
Restructuring 181 0.7 63 0.3
Earnings before provision for taxes on income 34 0.1 7,493 31.2 (99.5)
(Benefit from)/Provision for taxes on income (176) (0.7) 2,341 9.7 (107.5)
Net earnings 210	$ 0.8 5,152	$ 21.5 (95.9)
Net earnings per share (Diluted) 0.09	$ 2.12	$ (95.8)
Average shares outstanding (Diluted) 2,448.6 2,428.6
Effective tax rate (517.6) % 31.2 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 7,672	$ 30.2 8,436	$ 35.2 (9.1)
Net earnings 6,339	$ 25.0 6,801	$ 28.3 (6.8)
Net earnings per share (Diluted) 2.59	$ 2.80	$ (7.5)
Effective tax rate 17.4 % 19.4 %
(1) See Reconciliation of Non-GAAP Financial Measures.
THIRD QUARTER
2026 2025

-- 9 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 74,771	$ 100.0 69,629	$ 100.0 7.4
Cost of products sold 24,254 32.4 22,288 32.0 8.8
Gross Profit 50,517 67.6 47,341 68.0 6.7
Selling, marketing and administrative expenses 18,751 25.1 16,923 24.3 10.8
Research and development expense 11,832 15.8 10,413 15.0 13.6
In-process research and development impairments 375 0.5 - -
Interest (income) expense, net 136 0.2 (62) (0.1)
Other (income) expense, net 6,405 8.6 (7,692) (11.1)
Restructuring 247 0.3 144 0.2
Earnings before provision for taxes on income 12,771 17.1 27,615 39.7 (53.8)
Provision for taxes on income 1,792 2.4 5,927 8.6 (69.8)
Net earnings 10,979	$ 14.7 21,688	$ 31.1 (49.4)
Net earnings per share (Diluted) 4.49	$ 8.94	$ (49.8)
Average shares outstanding (Diluted) 2,445.8 2,424.8
Effective tax rate 14.0 % 21.5 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 24,153	$ 32.3 24,635	$ 35.4 (2.0)
Net earnings 20,034	$ 26.8 20,206	$ 29.0 (0.9)
Net earnings per share (Diluted) 8.19	$ 8.33	$ (1.7)
Effective tax rate 17.1 % 18.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
NINE MONTHS
2026 2025

-- 10 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 7.7% 2.5% 5.9%
U.S. 11.1% 4.8% 9.1%
International 2.4% 0.1% 1.5%
WW Currency (0.2) 0.0 (0.1)
U.S. - - -
International (0.6) 0.0 (0.3)
WW Operational 7.9% 2.5% 6.0%
U.S. 11.1% 4.8% 9.1%
International 3.0% 0.1% 1.8%
WW Adjusted Operational Ex A&D 8.0% 2.5% 6.1%
U.S. 11.1% 4.8% 9.1%
International 3.2% 0.1% 1.9%
Adjusted Operational Sales Growth
THIRD QUARTER 2026 ACTUAL vs. 2025 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 11 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 8.8% 4.9% 7.4%
U.S. 9.9% 4.8% 8.3%
International 7.2% 4.9% 6.2%
WW Currency 1.4 1.4 1.4
U.S. - - -
International 3.6 2.7 3.2
WW Operational 7.4% 3.5% 6.0%
U.S. 9.9% 4.8% 8.3%
International 3.6% 2.2% 3.0%
Caplyta (0.6) (0.4)
U.S. (1.0) (0.7)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1
U.S. 0.0 0.1 0.0
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 6.9% 3.6% 5.7%
U.S. 8.9% 4.9% 7.6%
International 3.8% 2.2% 3.1%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
NINE MONTHS 2026 ACTUAL vs. 2025 ACTUAL
Segments

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2026 2025 2026 2025
Net Earnings, after tax- as reported $210 $5,152 $10,979 $21,688
Pre-tax Adjustments
Litigation related 5,519 15 6,116 (6,894)
Intangible Asset Amortization expense 1,240 1,048 3,732 3,435
Restructuring related 1 195 168 533 302
Orthopaedics separation related 369 - 746 -
Acquisition, integration and divestiture related (34) 97 142 475
(Gains)/losses on securities 10 (387) (262) (327)
IPR&D impairments 339 - 375 -
Other - 2 - 29
Tax Adjustments
Tax impact on special item adjustments 2 (1,677) (168) (2,469) 826
Tax legislation and other tax related 168 874 142 672
Adjusted Net Earnings , after tax $6,339 $6,801 $20,034 $20,206
Average shares outstanding (Diluted) 2,448.6 2,428.6 2,445.8 2,424.8
Adjusted net earnings per share (Diluted) $2.59 $2.80 $8.19 $8.33
Operational adjusted net earnings per share (Diluted) $2.61 $8.04
Notes:
1
2
Third Quarter Nine Months Ended
In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline
operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment
costs. Restructuring expenses of $74 million in the fiscal third quarter of 2026 ($274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs.
In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the
network. Restructuring expenses of $80 million were recorded in the fiscal third quarter of 2026 ($194 million Q3 2026 YTD) and $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs
related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements.
The restructuring expenses of $41 million in the fiscal third quarter of 2026 ($65 million Q3 2026 YTD) and $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) includes costs related to market and product
exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

-- 13 of 17 --

Innovative Medicine
Third Quarter
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Third Quarter
September 27,
2026
Non-GAAP
Cost of products sold 4,486	$ (762) 18 (2) 3,740
Selling, marketing and admin expenses 3,035 3,035
Research and development expense 3,888 3,888
Other segment items 282 24 (92) (53) 4 165
Adjusted Income Before Tax by Segment 5,066 762 (24) - 74 55 (4) - - 5,929
MedTech
Third Quarter
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Third Quarter
September 27,
2026
Non-GAAP
Cost of products sold 3,597	$ (478) (13) (6) 3,100
Selling, marketing and admin expenses 3,014 (38) 2,976
Research and development expense 764 (5) 759
Other segment items 491 22 (339) (108) 95 (14) (320) (173)
Adjusted Income Before Tax by Segment 776 478 (22) 339 121 (95) 14 369 - 1,980
Expenses not allocated to segments
Third Quarter
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Third Quarter
September 27,
2026
Non-GAAP
Cost of products sold 14	$ 14
Selling, marketing and admin expenses 236 236
Research and development expense - -
Other segment items 5,558 (5,565) (6) (13)
Adjusted Income Before Tax by Segment (5,808) - 5,565 - - 6 - - - (237)
Johnson & Johnson Consolidated
Third Quarter
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Third Quarter
September 27,
2026
Non-GAAP
Cost of products sold 8,097	$ (1,240) 5 (2) (6) 6,854
Selling, marketing and admin expenses 6,285 (38) 6,247
Research and development expense 4,652 (5) 4,647
Other (Income) / Expense 5,780 (5,519) (19) 36 (10) (320) (52)
In-process research and development impairments 339 (339) -
Interest (Income)/Expense 31 31
Restructuring 181 (181) -
Adjusted Income Before Tax 34 1,240 5,519 339 195 (34) 10 369 - 7,672
(Benefit from)/Provision for taxes on income (176) 239 1,230 85 37 18 - 68 (168) 1,333
Net Earnings 210 1,001 4,289 254 158 (52) 10 301 168 6,339
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 14 of 17 --

Innovative Medicine
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 3,672	$ (568) (11) 3,093
Selling, marketing and admin expenses 2,869 2,869
Research and development expense 2,944 2,944
Other segment items (368) 5 (48) 174 (1) (238)
Adjusted Income Before Tax by Segment 6,446 568 (5) - 59 (174) - 1 6,895
MedTech
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 3,612	$ (480) (12) (1) 3,119
Selling, marketing and admin expenses 2,801 2,801
Research and development expense 728 728
Other segment items 2 5 (156) (48) 213 (1) 15
Adjusted Income Before Tax by Segment 1,287 480 (5) 168 49 (213) - 1 1,767
Expenses not allocated to segments
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 19	$ 19
Selling, marketing and admin expenses 252 252
Research and development expense - -
Other segment items (31) (25) 11 (45)
Adjusted Income Before Tax by Segment (240) - 25 - (11) - - - (226)
Johnson & Johnson Consolidated
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 7,303	$ (1,048) (12) (12) 6,231
Selling, marketing and admin expenses 5,922 5,922
Research and development expense 3,672 3,672
Other (Income) / Expense (478) (15) (93) (85) 387 (2) (286)
In-process research and development impairments - -
Interest (Income)/Expense 18 18
Restructuring 63 (63) -
Adjusted Income Before Tax 7,493 1,048 15 168 97 (387) - 2 8,436
Provision for taxes on income 2,341 193 3 34 16 (87) (874) 9 1,635
Net Earnings 5,152 855 12 134 81 (300) 874 (7) 6,801
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 15 of 17 --

Year to Date
Innovative Medicine
Nine Months
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Nine Months
September 27,
2026
Non-GAAP
Cost of products sold 13,172	$ (2,289) (21) 10,862
Selling, marketing and admin expenses 9,083 9,083
Research and development expense 9,576 9,576
Other segment items 104 75 (274) (153) 286 38
Adjusted Income Before Tax by Segment 16,632 2,289 (75) - 274 174 (286) - - 19,008
MedTech
Nine Months
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Nine Months
September 27,
2026
Non-GAAP
Cost of products sold 11,035	$ (1,443) (55) (9) 9,528
Selling, marketing and admin expenses 8,989 (55) 8,934
Research and development expense 2,256 (7) 2,249
Other segment items 732 139 (375) (204) 31 (24) (675) (376)
Adjusted Income Before Tax by Segment 3,192 1,443 (139) 375 259 (31) 24 746 - 5,869
Expenses not allocated to segments
Nine Months
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Nine Months
September 27,
2026
Non-GAAP
Cost of products sold 47	$ 47
Selling, marketing and admin expenses 679 679
Research and development expense - -
Other segment items 6,327 (6,330) 1 (2)
Adjusted Income Before Tax by Segment (7,053) - 6,330 - - (1) - - - (724)
Johnson & Johnson Consolidated
Nine Months
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Nine Months
September 27,
2026
Non-GAAP
Cost of products sold 24,254	$ (3,732) (55) (21) (9) 20,437
Selling, marketing and admin expenses 18,751 (55) 18,696
Research and development expense 11,832 (7) 11,825
Other (Income) / Expense 6,405 (6,116) (231) (121) 262 (675) (476)
In-process research and development impairments 375 (375) -
Interest (Income)/Expense 136 136
Restructuring 247 (247) -
Adjusted Income Before Tax 12,771 3,732 6,116 375 533 142 (262) 746 - 24,153
Provision for taxes on income 1,792 718 1,361 93 161 63 (63) 136 (142) 4,119
Net Earnings 10,979 3,014 4,755 282 372 79 (199) 610 142 20,034
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 16 of 17 --

Year to Date
Innovative Medicine
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 11,670	$ (2,002) (24) 9,644
Selling, marketing and admin expenses 7,919 7,919
Research and development expense 8,361 8,361
Other segment items (520) 74 (275) 164 (14) (571)
Adjusted Income Before Tax by Segment 17,208 2,002 (74) - 299 (164) - 14 19,285
MedTech
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 10,576	$ (1,433) (35) (52) 9,056
Selling, marketing and admin expenses 8,319 8,319
Research and development expense 2,052 37 2,089
Other segment items 132 (78) (267) (155) 163 (15) (220)
Adjusted Income Before Tax by Segment 3,912 1,433 78 302 170 (163) - 15 5,747
Expenses not allocated to segments
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 42	$ 42
Selling, marketing and admin expenses 685 685
Research and development expense -
Other segment items (7,222) 6,898 (6) (330)
Adjusted Income Before Tax by Segment 6,495 - (6,898) - 6 - - - (397)
Johnson & Johnson Consolidated
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 22,288	$ (3,435) (35) (76) 18,742
Selling, marketing and admin expenses 16,923 16,923
Research and development expense 10,413 37 10,450
Other (Income) / Expense (7,692) 6,894 (123) (436) 327 (29) (1,059)
In-process research and development impairments - -
Interest (Income)/Expense (62) (62)
Restructuring 144 (144) -
Adjusted Income Before Tax 27,615 3,435 (6,894) 302 475 (327) - 29 24,635
Provision for taxes on income 5,927 603 (1,541) 58 118 (73) (672) 9 4,429
Net Earnings 21,688 2,832 (5,353) 244 357 (254) 672 20 20,206
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 17 of 17 --